VolitionRx Limited (VNRX) 12 May 222022 Q1 Earnings call transcript

Good morning, ladies and gentlemen. Thank you for standing by. Welcome to VolitionRx Limited's First Quarter 2022 Earnings Conference Call.

During today's presentation, all parties will be in a listen-only mode.

Following the presentation, the conference call will be open for questions. is today, conference XX, This Instructions] being May recorded XXXX. [Operator Relations. to I Executive conference Investor would now, turn Vice now of Powell, And Scott like the to call President over Please go ahead.

upcoming call today's Thank and call Limited. activities financial first for welcome, recent operating to quarter along key will you, discussion earnings of of Volition's cover our milestones. XXXX, everyone, for conference VolitionRx results the and This with and a

session. Also conference Chief Following question-and-answer and our Officer. Butera, Financial call will Mr. of are subsidiary; the remarks, Executive Officer Hughes, Volition our Tom and our prepared to on Cameron we open Dr. Chief President today Executive Chief Terig Veterinary call a Reynolds, Officer;

on that results these risks, be results, this statements involve concerning call cause different events, forward-looking a views I'd statements. future assumptions reflect the harbor are covered we have based of results or include begin, safe as of available current conference under performance, actual based to expressed from vary our statements on to our number factors Because by statements achievements Actual the these information statements These as significantly we and Act of based Litigation these may that Reform like on or currently assumptions. Securities discussed beliefs upon the uncertainties implied events us. some future XXXX. future may materially Private to provisions everyone or will Before information remind of used the well

and call. to forward-looking to reports Securities of Chief Commission. XX-Q, other associated obligation do Executive operations. during XX-K, Cameron Annual with now on Cameron? In Form our Mr. our We and President over update turn like an quarterly I'd recent have made Report Reynolds. to course the statements We identified and risk most our call Form filings with Exchange factors undertake various Officer, not on any the the this

XXXX quarter earnings We appreciate Volition's you for especially the thank everyone and earnings Scott, your call time joining first Thanks, busy season. given today. call

and of activities we our Dr. with be Volition May up We will Executive a our work. the joined a.m. report case XX the I Volition wrap just ongoing call XX update debt, financial then, Chief missed time. Butera, And will quick we given hosting of Capital an our previous But then at all Officer Tom commence Veterinary. exciting are delighted Markets with in first announcements, by tomorrow, day XXXX to U.S. you are Eastern surrounding advertisement,

attend person or volition.com You website might Investor webcast. join just to in found be very register Relations section. NYSC the else in at you both the welcome be to Details our are in on to time the for can via

tomorrow indeed but call to Given to usual, be the tight, the update. happy over we And that, capital we'll and markets quite filing fairly I with XX-K, you this aim will for financial the our any answer to Terig questions of presentation have. recent hand as might

them million $XX.X and supply of position the XXXX. licensing milestone executed earnings the with approximately on the Heska quarter Thanks end cash XX, very now includes with cash to XX, the received We for will thank $XX.X relation for financial and an of summary equivalents call This at March in compared cash XXXX. provide of our today. payments key ended you ended million upfront joining Corporation much, Cameron, everyone $XX agreement a billion and of with quarter results the I March XXXX. from

lower expenses million of the million XXXX. in to was Total of functions, carefully, continue higher stock-based general expenses first our first manage of the increased in the from $X.X XXXX. personnel as additional the P&L, was tests of Vet Singapore mainly the HX.X Q. increase well Europe, costs to XXXX Nu.Q costs well was in as quarter three prior compared research for Discover to of and first months to as the March primarily $XX,XXX the million reported as year. compared compensation comparison first due expected, Revenue Year-on-year the quarter to result last Overall, overall while the of a we marketing sale in $X.X and loss primarily customers of as the first million quarter our headcount for This quarter were first in quarter but as of compared Net the for has result XX, in administrative sale also $X.X sales charges. sale to $X.X included increased initial primarily to XXXX to year. level quarter of first $XXX,XXX operating quarter versus and the expenditures was in ended increase expenditure was the on Moving Nu.Q of in of to quarter SAGE the XXXX. higher the development for

is of combination truly received payment million Heska work commercial our journey. of across previously, milestone Corporation. beginning milestone marked only much was a also the of Company $XX from milestone. we mentioned company cash the upfront The revenue accounting As payment but recognized fully relevant This it's an for revenue with It from a not in in accounted payment, and period XXX in ASC contracts been revenue with worth deferred standard and accordance noting as the non-refundable, and whilst been it this as has has has customers. been received that the not

ASC near our Heska, XXX predict complexity it update our in difficult this to we is relation around point; agreement to in to outlook with at however, aim revenue the the future. Given you

cover and call markets previous tomorrow. but capital the in some on discussed plan event details, our to we As

from Vet forward regarding range, supply develop in activities in to addressable for also on notably our not upcoming And accessing We over only are details believe significant, we very and Nu.Q due we but in you further with NET. Given most to the proprietary believe can markets the that, I'm Dr. to course look milestones updating Heska short-term our Veterinary. will progress opportunities. And who and Nu.Q licensing Butera, other Tom? delighted Volition provide our Nucleosomics the Tom these with hand product we platform. and agreements,

to prouder and and hello Corporation. really It of and partnering honestly network. for XXXX worldwide so cost, we much veterinary distribution provider be time Thanks specialty rapid, generation the March, has a I more advanced a everybody. today. am Vet a leading leading our the can for of our achievement not and global announced Heska to with outcomes you how I I very much, of care believe is developing next first animals. about bullish save low call as contract, quarter breakthrough securing for our update even diagnostics work deal This say commented ethic dedicated on improve of one has really that millions of this pets since philosophy, licensing the and When in to companies a lives and proud point have all Nu.Q of help in to very so been I this and sharing diagnostic Heska products is that veterinary. worldwide. supply vision in global could Terig, of And industry's companion today. Heska of I

towards sales up and running and and streams the progress work from making launch. to many tremendous have marketing logistics transfer and are We technical

provides for point companion our of executed sell animals As Test to Heska care. rights Cancer agreement a at Volition's with Vet the reminder, exclusive Nu.Q

to questions and Terig the the Test companion has to payment finally in payments, as the commercialize rights ongoing it the spoken the licensing via exclusive last call, $XX laboratories. for a and reference potentially non-exclusive we Vet financial received to looking to addition to this there from of to sell rights the subsequent million, into multiyear some This components. Nu.Q for up $XX to supply animals provides milestone point Heska I as feline of about totals Cancer certain at in confusion rights for cancer elements agreement of of was deal. things monitoring kits first companion which understand surrounding well tests kits upfront some million addition again global the the get. test In menu and And future, animals wider of canine lymphoma

more receive while the to milestones, $XX midterm Volition. received $XX payment signing I agreement, Volition breakdown, I will you for don't milestone like provides which wish so on provide hopefully and and Heska million myself to This with the of upfront $XX too a To to based give much, payments near anticipate clarity. a And up would little repeat million tender million to receiving a of achievement XXXX. we the upon contract in

that product supply sells these that kit to a and be sold in in are Every likely most is and we deal And make of the with for through key a test, for payments, than that millions of the greater where for revenue is this or a sale expect sale of to each significantly to potential these components receive will market. exclusive Volition the used addition Volition will year. of bring market the be point-of-care long-term which the a from component. market the kits, expects Heska payment ongoing incredible payments, time the key In tests Heska lab relation will money, reference to milestone

for say talking in SAGE And be a both early the year, could and the later certainly Test get XXXX. if this ongoing launched legal of to launch webinar, quarter of subsequent to deal presenting we the to Dr. to as Healthcare veterinarians early honor not, the Nu.Q and preparing a I'm excited significant. to So, possibly by via finish launch Singapore. hosted for for fantastic companies. revenue Cancer delighted SAGE. the end, on And Wilson-Robles in It's Volition work I as had Vet launches are Singapore but

in of With word simple, interest them SAGE this blood to a are progress negotiations, to I ever that, team I driving year. of pleased the say more tests the there now optimistic in and We I easy lot quarters. addresses signing regards use Veterinary deals ever, are our market. huge further clinic, and was to I other in am these spreading certainly as a questions expect great remain believe provide the remain to the that know calendar updates the is we need lot making this coming and in than unmet a and ongoing. As

As Cancer I as the blood health, previous it Nu.Q as in is animal cancer Test significantly, in could But believe, human manage screening transform Vet have health. like yet cancer how in animals. tests on commonplace companion significantly, said veterinarians I firmly not is calls,

cancers, and Wilson-Robles team call further Nu.Q I'm Vet delighted may the have more both with data work Society working will dogs also the the this expanding excitingly didn't disease month coming asked Wilson-Robles test. of with stop in using to screening Veterinary early their volition tool, fourth to and regard Nu.Q response the publicly the monitoring serve of whole Market in of Vet a Congress Cancer this and diseases. discussed able Not Nu.Q monitoring data disease I at at minimal able to else test incredibly need view cancer. presented to monitoring dog's identify help an In well disease an say quarter get but also time that Vet last cancer we Veterinary, the Dr. has useful the more tomorrow real at as here, like us a as be believe have on many commend on relation screen only use in being but remission Volition today XXXX. veterinary not work, Nu.Q be I product, Wilson-Robles activities sure potential helping then in on meeting Society clinical presenting per Volition Vet and for and catch of done. is Capital that, the for monitor time, of and expanding for up, thank will the progression meet hope I a treatment details and unmet a busy as many to the keep out of current providing to well, you great or today to of of the Sicily. Our sensitive for earlier, for too the later ongoing a would I job technical Oncology European Day on All-in-all, it test Dr. a be the the executives to hard be the short. many a Dr. team use market. a We as detects, very team range dog join to that, but Veterinary be our residual remission test test indication and could been the the on as Veterinary to we of was as can tremendous will measurement to

with that, Cameron. hand So I'll it back to

supply very a with could now happier the of the but excited deals ongoing businesses quarter industry's a add outcome we and one some have with for from I of Heska, stream team's in global be much, talented pipeline. a to not not strengthen the aspects people, ever am of proud I only It other view moving purely the Healthcare. and achievement Tom. leading the wide Could securing XXXX, development like of our of we especially fast recruits, I'm the everything products. our teams and Heska time generate veterinary with a in not a licensing of and both payments, be to components, with and Thanks with Tom of of team. have we the progress and starting expanded the our made the also companies, as as potential with research to in on in bench note, part incredibly also business Company is Corporation. I'd company sales progress the the with key and And that vet in personal explained terms team key range I of this could in contract exciting as revenue on and the and delighted business from our significant to have commercial the to kits strongly an company revenue SAGE clear first to with milestone commercial pillar take

within Sharon health be say Thermo the through the industry senior to regulatory the of Siemens including at Quality for Sharon. lead Head risk management, U.S. style, which welcome Agena Ballesteros experience at on Nu.Q Capital and quality control Volition with strategy and FDA Design, and tomorrow I'm in in hits over Fisher, you Bioscience great Markets running Sharon process was will Day, absolutely processes. presenting GRAIL, programs. to the Director clinical at Additionally, as quarter we ground Sharon and has Development years of and end, the design Quality Sharon Risk and Company's board delighted subsequent vitro XX and diagnostics, most program improvement NETs assurance, strategy the for roles recently, diagnostic have program

key Company next is our Our product. of element the

Nu.Q We one which have product pillars, with to five Vets. of Tom earlier covered regards

Cancer to have regarding updates detail Micallef weeks last it Jake call, since programs. Day NETs cover on only or Further, Markets today. been brief his just and has provide Discover few thunder, Nu.Q Nu.Q Given will Capture update a fully as our tomorrow Capital we Nu.Q I so significant no our will steal Nu.Q a not in at the

will and with has technology on identify Nu.Q Nu.Q enrichment thereby when As which amplifying diagnosis, technology Nu.Q analysis previous background and/or transformational program spectrometry factors remove potentially Nu.Q Capture essentially now could disease as either Capture generation Capture be fragments and believe treatment I've by novel we and sequencing essays. a sequencing. spectrometry selection the signal several technology nucleosomes treatment mass the a which DNA and both parameters next including calls, the combination in The isolating DNA aid strands said noise way. or in and used monitoring various transcription plasma Other technology, from of for of signal mass strands involves looks to either

over in very and Dr. Professor Subsequent and to different lab, genome opinion biopsy and are very Belgium and well the companies, exciting included key our Terry four question are web are we which you It of many busy Kelly. demand catch-up. in were Capture webinar, to a strands actively interest Should on year-end, Nu.Q on This sponsor We Axel currently our all in session working the of featured own the Imhoff webinar we industry, available which a with potentially liquid the spanning interested, areas. still leader California XXX new delighted undertaking. attendees demonstrating epigenetics academia. product leading including in is webinar incredibly answer received was and be work

contact For please mediarelations@volition.com. more details,

July Aswani. sponsoring Andrew webinars Dr. genome will be NETosis also one leading Care the Consultant, next with web Intensive We focused due with future on late

close, In much this conclusion, and very webcast. studies, many on like I much see who that not I and to sharing at much joining position results call the so a journey. quarter today. well this will drawing further call of about quarters. the be call if Capital rest I'm be with for the now to significant season. and next carried to able And are in indeed focus an to the by We momentum joined our positive look team members Nu.Q regarding questions. excited Nu.Q I has board milestones second strong Markets made months more the further take I delighted Nu.Q and we hope our phase thank so and other heart many clinical is Day of executive news We're our earnings not of details earnings appreciate Operator? you NET. as publications the Vet I all the many you it tomorrow. of time join the share over into commercialize very with and given progress you're coming the platform feel Vet in extremely in very could first epigenetics, company XXXX of key to about forward to our Nu.Q whole work happy along subsidiaries, to I'd a areas. and in this as the for at of we I'm quarter. the But our person,

go Please ahead. session. Osborn the first Cantor the comes question Instructions] We'll now begin And [Operator Fitzgerald. with question-and-answer Ross from

more some your and payments? million could of XX off, milestone little you Starting incremental directory a maybe recognizing the into bit insight provide

Yes.

that? with to So, Terig, do want you deal

year. the million, as the So, given that time the firm what quarter of how out to But give XX to first to treated to as in this this work point. to at bit but we contract, the probably said, likely take call, in recognize bank relation quarters. the respect we're going money the so this and point, we've over respect with that coming update that to are at going to accounting look this million deferred similarly, for on like. exactly its to you on difficult next we're complexity the going The on around And and XX to a non-refundable, we revenue that is with guidance it's that's other and

it's to think and important I to But out also Ross very point listening. everyone

be The other we think first three which milestones. year, to second early the next there, this achievable is what products, the XX later as be hopefully market, and line we million very could months is year the product, an kind on what actual fee well. which are just in as is Heska launch which the CEO of of The then on year, XX next And would expecting the well. option next of expect

that's So, two next a which between goes think a our I the think is assumption. $XX the to we I and long the over years, get the way assuming buttressing million, burn reasonable XX, XX which others,

we And expect achieved kit so, happier. from be the when those revenue to very kicks very, in, milestones, we then that's which well. have couldn't be also as would sales, And meaningful the we we expect once

long have dealing money of start with in, will far way our I our go rate. to as So, to really so we drastically a burn can changes coming think it lot position a overall which

$XX So, the milestone and payments. we're the potential ongoing both extremely with revenue happy million

to remind as any an now? then can provide contract, each switching more great. to then And to if is It you signed how which a can contracts? little understand be phase in, least then, And new you visibility have better a maybe there? at sounds potential Discover's clarity or bit us And Okay. provide we average, would many over so revenue would follow-up, contract able you on the you

Terig?

Yes.

XX-K. the call an much not on the last since is there So, of update

that and on five contracts average have to average expect got we signed year. We this around is somewhere the realize $XX,XXX

for XXX,XXX of a to other as terms we we signed pipeline So, the with contracts year. at couple also about got looking are But we a contracts this materialize expect just then, year in of this have well. that

I going show So, we're looking forward, probably going emphasis. for Ross's year. we're our say just where to XXX,XXX to be this to at just to somewhere And put between think important XXX,XXX

to to So you'll on great think XX,XXX Discover's everything for But, get I tomorrow, much. and Markets year. very exciting this last Day is the for see you'll Capital compared that see other revenue advertising very

market addressable total between is NETosis for the $XX think and them. Vet billion I about

we will those the good, heart put effort the get of into think, at very would to it's some contracts, of great a So addressable and epigenetics, great total but Discover. Discover is fraction market we

going not are a think we to lot are given big I we of a company, So effort. put

from for who a us the side lot the U.S. from side. regulatory hear on directly You'll strategy tomorrow NETosis about joined FDA GRAIL Sharon, just

not in is Discover same the elephant NETosis So about but an it, excited is. we're it's and important potentially Vet and way

it's So, the the will, what like going revenue if elephant country going to really look we be focus were and going on to and you forward. will how get tomorrow

that mind never massive going the So, just as good us, never Discover in massive. to going for side, a it's but to as is, it market it's be be keep on

Okay.

able you where grow fully better of than think little me, you control to to forecasting. last Could bit to for and the bit understand are you'll maybe continue forward were here? expenditures year to about maybe tomorrow. a maybe And we able then the help you us Looking one where are rest just

cash it burn than cash little bit some a burn, the X the heavier of year, above data the expenditures of not was of ticked terms the a has is balance quarter. million, but in in of because much. yes, first the the bit, somewhere of up But we're little us quarter just first So, underlying for

same compared period under you'd control. up bit it ticked it's, last it's to as So still but year, expect, little well a the

where want out very And we spending it's But wisely. we're to, And to point we'd little difficult make think conditions time, below we the money I something. really sure thought out obviously, just there our market and to were, we a Yes, same at that's the I again, Thank trying need get think commercializing you. projections be. products. are the our start moment, we're to at we

think made I how the to NET's from show about can much can the see space, made can Vet's space. much money be you how from we're be

but I revenue, So message sure deliver think team, we've fantastic because we tight, everybody it's a money. one got balance and making of great keeping clear loud make from platform, but some it is

So, to tight think you're in spending money, we're space. money the well very proved aware we moment more think I balancing make little has space. of there I But overall Vet sure markets successful which very at a will keep rough because the it in paycheck out I'm the the

make want is wisely. sure dollar every we So, spent very to

a in in. were are were sense. while revenue. position in money that keep a But quite last come things we okay was already financial than makes to quarter, getting tight we given If we've rein the on we all which You sure better going making invest

questions. for Instructions] time have still [Operator We

as a I've informed just sorry, line. issue on been phone technical Actually, the

got we've Markets Given we tomorrow, to that Capital the questions. fact Day answering a will be

We answer have look can with two a all the the its we fully have. Markets second on the longer given of longer tomorrow, but session this And questions. time rest calls who are some more is understand we to half cannot, hour much perhaps take and but given I the Day. them Capital a tomorrow trying get anyway, analysts

line, to Capital call who or the the happy trying those on to phone take I'm Day. Markets So on get very tomorrow, are the those technical today, for given but issue down the I questions apologize

you wrap I to much. very So up, thank

we I think be I happier with are. where couldn't

stronger growing, we wide And of I think hear very a how good tomorrow, very few a that a how think portfolio people. I be products. our deeper, from patent developing quite has of was are a our heard you've of how lot will range and grown team you'll indication

Vet have to not from forward where the path and from we're NETosis. going and You about also making the for hearing Volition, space, revenue you're before be heard the on perhaps

position. incredibly think overall, in good we're So I

now really to spent us we've we're we great I we put think great the commercialize has are a XX in forward what have strategy now, where years doing. a position and going

who event be Hope tomorrow update for So, your And quarter. in York you Thank online. I or lot of great a the think there live you to of live those or much you lot New It's a please attend going a should can, time. Stock person. more very on. next Exchange

few And you. to I great more months. have Thank look great to presenting soon. day. forward you updates a Have So a

is conference you disconnect. may you Thank today's The now attending concluded. for and now presentation